Compare UPBD & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPBD | JANX |
|---|---|---|
| Founded | 1986 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 975.7M |
| IPO Year | 1996 | 2021 |
| Metric | UPBD | JANX |
|---|---|---|
| Price | $15.81 | $16.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $32.25 | ★ $47.00 |
| AVG Volume (30 Days) | 784.7K | ★ 833.6K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 8.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $4,695,061,000.00 | $10,000,000.00 |
| Revenue This Year | $5.96 | N/A |
| Revenue Next Year | $6.47 | N/A |
| P/E Ratio | $16.11 | ★ N/A |
| Revenue Growth | ★ 8.67 | N/A |
| 52 Week Low | $15.37 | $12.12 |
| 52 Week High | $23.98 | $35.34 |
| Indicator | UPBD | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 25.65 | 45.11 |
| Support Level | N/A | $15.75 |
| Resistance Level | $19.67 | $16.68 |
| Average True Range (ATR) | 0.49 | 0.75 |
| MACD | -0.15 | -0.17 |
| Stochastic Oscillator | 14.33 | 24.16 |
Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has four operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions, Mexico segment offers lease-to-own stores in Mexico. The The Brigit segment offers various financial health products and tools to help users improve their financial health. The company derives a majority of its revenue from the Acima segment.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.